Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. MLSS
MLSS logo

MLSS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Milestone Scientific Inc (MLSS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
0.300
1 Day change
5.33%
52 Week Range
1.110
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Milestone Scientific Inc (MLSS) is not a strong buy for a beginner, long-term investor at this time. The company's financial performance has been declining, insider selling has significantly increased, and there are no positive catalysts or strong trading signals to support an immediate investment decision. Given the lack of positive sentiment, weak financials, and neutral technical indicators, it is better to hold off on investing in this stock for now.

Technical Analysis

The MACD is positive and expanding, indicating a mild bullish trend. RSI is in the neutral zone at 66.236, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 0.269 with resistance at 0.292 and support at 0.246.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
10

Positive Catalysts

  • NULL identified. No recent news or significant positive developments.

Neutral/Negative Catalysts

  • No recent congress trading data or influential figure activity.

Financial Performance

In Q3 2025, revenue dropped by -6.11% YoY to $2,360,117. Net income fell by -21.03% YoY to -$1,153,959. EPS declined by -50.00% YoY to -0.01. Gross margin decreased by -5.54% YoY to 68.67%. Overall, the company's financials show a negative growth trend.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for MLSS.

Wall Street analysts forecast MLSS stock price to rise
2 Analyst Rating
Wall Street analysts forecast MLSS stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.281
sliders
Low
1
Averages
1
High
1
Current: 0.281
sliders
Low
1
Averages
1
High
1
Benchmark
Speculative Buy
downgrade
$1
AI Analysis
2025-11-20
Reason
Benchmark
Price Target
$1
AI Analysis
2025-11-20
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Milestone Scientific to $1 from $1.25 and keeps a Speculative Buy rating on the shares. Sales traction for the Medical business has proven to be elusive, so the firm is lowering its forward revenue estimates, noting that its 2030 revenue estimate of $22M is discounted to the end of 2026 at 8.2% to arrive at its lowered price target.

People Also Watch